Esperion Therapeutics

ESPR

Market cap $524M

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

NEW YORK and ANN ARBOR, Mich., April 02, 2026 (GLOBE NEWSWIRE) -- Athyrium Capital Management, LP and Esperion Therapeutics, Inc. (Nasdaq: ESPR) today announced the entry into a $50 million royalty financing agreement under which certain funds managed by Athyrium Capital Management (the “Athyrium Funds”) will acquire 100% of Esperion's royalty interest, held by Esperion pursuant to that certain License and Collaboration Agreement, dated as of April 17, 2020, as amended, by and among Esperion and Otsuka Pharmaceutical Co., Ltd (“Otsuka”), of Otsuka's net sales of bempedoic acid products in Japan from and after January 1, 2026, together with related regulatory and commercial milestone payments, subject to a cap.

–  Enbumyst, First and Only FDA-Approved Nasal Spray Loop Diuretic Now Integrated into Esperion's Cardiovascular Franchise, Anticipated to Drive Portfolio Expansion, Commercial Leverage, and Continued Revenue Growth –

– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –

Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.

Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript

Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.

– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –

Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.

Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript